Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Polyus sold all shares in Lenzoloto

4/16/24 LNZL

Moscow and Beijing have not yet been able to agree on the price of Power of Siberia 2

4/16/24 GAZP

En+ Group invest to JV with CHN Energy about ₽50 billion

4/16/24 ENPG

Transneft reported for Q1 2024 under RAS

4/16/24 TRNFP

Yandex launched a search with artificial intelligence Neuro

4/16/24 YNDX

Izhstal reported for 2023 by IFRS

4/16/24 IGST

Board of Directors of Alrosa recommended dividends

4/16/24 ALRS

NCSP in Q1 increased transshipments by 23%

4/16/24 FESH

Nefaz reported for Q1 2024 by RAS

4/16/24 NFAZ

Cyprus has allowed MD Medical to redomicile

4/16/24 MDMG